Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 2/2018

01-02-2018 | Original paper

Delivery of adjuvant chemotherapy among stage III colon cancer patients at a public versus private hospital in New York City

Authors: Daniel Lin, Judith D. Goldberg, Tsivia Hochman, Benjamin A. Levinson, Maria Khan, Elliot Newman, Lawrence P. Leichman, Heather T. Gold

Published in: Cancer Causes & Control | Issue 2/2018

Login to get access

Abstract

Purpose

Prior studies of timeliness of adjuvant chemotherapy (AC) initiation in stage III colon cancer have suggested longer time to AC at public compared with private hospitals. Few studies have explored differences in AC completion. We investigated whether timely initiation and completion of AC differed between a public and private hospital, affiliated with the same academic institution in a large, urban setting.

Methods

We conducted a retrospective cohort study of stage III colon cancer patients who had surgery and AC at the same medical center between 2008 and 2015, either at its affiliated public hospital (n = 43) or private hospital (n = 79). We defined timely initiation as receiving AC within 60 days postoperatively, and completion as receiving ≥ 75% of planned AC. Univariate and stepwise multivariable logistic regressions were used to identify factors associated with AC delivery.

Results

Median number of days to AC was significantly greater among patients at the public (53, range 31–231) compared with the private hospital (43, range 25–105; p = 0.002). However, the percentage of patients with timely AC initiation did not differ substantially by hospital (74 vs 81%, p = 0.40). In multivariable analysis, age (OR 0.95/year, 95% CI 0.91–0.99) and laparoscopic versus open surgery (OR 5.65, 95% CI 1.92–16.62) were significant factors associated with timely AC initiation. Moreover, AC completion did not differ significantly between public (83.7%) and private (89.9%) hospital patients (p = 0.32).

Conclusions

The proportions of patients with timely initiation and completion of AC were similar at a public and private hospital affiliated with a large, urban medical center. Future research should investigate how specific system-level factors help alleviate this expected difference in timely care delivery.
Appendix
Available only for authorised users
Literature
1.
2.
O’Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ et al (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15(1):246–250CrossRefPubMed
3.
Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116CrossRefPubMed
4.
Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29(11):1465–1471CrossRefPubMed
5.
Des Guetz G, Nicolas P, Perret GY, Morere JF, Uzzan B (2010) Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 46(6):1049–1055CrossRefPubMed
6.
Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM (2011) Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 305(22):2335–2342CrossRefPubMed
7.
Bos AC, van Erning FN, van Gestel YR, Creemers GJ, Punt CJ, van Oijen MG et al (2015) Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur J Cancer 51(17):2553–2561CrossRefPubMed
8.
Hershman D, Hall MJ, Wang X, Jacobson JS, McBride R, Grann VR et al (2006) Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 107(11):2581–2588CrossRefPubMed
9.
10.
Massarweh NN, Haynes AB, Chiang YJ, Chang GJ, You YN, Feig BW et al (2015) Adequacy of the national quality forum’s colon cancer adjuvant chemotherapy quality metric: is 4 months soon enough? Ann Surg 262(2):312–320CrossRefPubMedPubMedCentral
11.
Silber JH, Rosenbaum PR, Ross RN, Niknam BA, Ludwig JM, Wang W et al (2014) Racial disparities in colon cancer survival: a matched cohort study. Ann Intern Med 161(12):845–854CrossRefPubMed
12.
Klepin HD, Tooze JA, Song EY, Geiger AM, Foley KL (2013) Age-related treatment disparities among medicaid beneficiaries with metastatic colorectal cancer. J Gerontol Geriatr Res 2(4):134PubMedPubMedCentral
13.
Hsieh MC, Chiu YW, Velasco C, Wu XC, O’Flarity MB, Chen VW (2013) Impact of race/ethnicity and socioeconomic status on adjuvant chemotherapy use among elderly patients with stage III colon cancer. J Regist Manag 40(4):180–187
14.
Gorey KM, Luginaah IN, Bartfay E, Fung KY, Holowaty EJ, Wright FC et al (2011) Effects of socioeconomic status on colon cancer treatment accessibility and survival in Toronto, Ontario, and San Francisco, California, 1996–2006. Am J Public Health 101(1):112–119CrossRefPubMedPubMedCentral
15.
Panchal JM, Lairson DR, Chan W, Du XL (2013) Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer. Clin Colorectal Cancer 12(2):113–121CrossRefPubMed
16.
Panchal JM, Lairson DR, Chan W, Du XL (2016) Geographic variation in oxaliplatin chemotherapy and survival in patients with colon cancer. Am J Ther 23(3):e720–e729CrossRefPubMed
17.
Roland CL, Schwarz RE, Tong L, Ahn C, Balch GC, Yopp AC et al (2013) Is timing to delivery of treatment a reliable measure of quality of care for patients with colorectal adenocarcinoma? Surgery 154(3):421–428CrossRefPubMed
18.
Yu S, Shabihkhani M, Yang D, Thara E, Senagore A, Lenz HJ et al (2013) Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. Clin Colorectal Cancer 12(4):275–279CrossRefPubMed
19.
Bayraktar UD, Warsch S, Chen E, Lima CM, Pereira D (2013) Comparison of cancer care and outcomes between a public safety-net hospital and a private cancer center. J Health Care Poor Underserved 24(3):1136–1149CrossRefPubMed
20.
Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478CrossRefPubMedPubMedCentral
21.
Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22):5401–5411CrossRefPubMed
22.
Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E et al (2010) Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 28(14):2418–2422CrossRefPubMedPubMedCentral
23.
Zeig-Owens R, Gershman ST, Knowlton R, Jacobson JS (2009) Survival and time interval from surgery to start of chemotherapy among colon cancer patients. J Regist Manag 36(2):30–41 (quiz 61–2)
24.
Crowley MM, McCoy ME, Bak SM, Caron SE, Ko NY, Kachnic LA et al (2014) Challenges in the delivery of quality breast cancer care: initiation of adjuvant hormone therapy at an urban safety net hospital. J Oncol Pract 10(2):e107–e112CrossRefPubMed
25.
26.
Christie J, Itzkowitz S, Lihau-Nkanza I, Castillo A, Redd W, Jandorf L (2008) A randomized controlled trial using patient navigation to increase colonoscopy screening among low-income minorities. J Natl Med Assoc 100(3):278–284CrossRefPubMed
27.
Ma GX, Shive S, Tan Y, Gao W, Rhee J, Park M et al (2009) Community-based colorectal cancer intervention in underserved Korean Americans. Cancer Epidemiol 33(5):381–386CrossRefPubMed
28.
Wang X, Fang C, Tan Y, Liu A, Ma GX (2010) Evidence-based intervention to reduce access barriers to cervical cancer screening among underserved Chinese American women. J Womens Health (Larchmt) 19(3):463–469CrossRef
29.
Raich PC, Whitley EM, Thorland W, Valverde P, Fairclough D, Denver Patient Navigation Research Program (2012) Patient navigation improves cancer diagnostic resolution: an individually randomized clinical trial in an underserved population. Cancer Epidemiol Biomarkers Prev 21(10):1629–1638CrossRefPubMedPubMedCentral
30.
Kilbourne AM, Pirraglia PA, Lai Z, Bauer MS, Charns MP, Greenwald D et al (2011) Quality of general medical care among patients with serious mental illness: does colocation of services matter? Psychiatr Serv 62(8):922–928CrossRefPubMed
31.
Pirraglia PA, Kilbourne AM, Lai Z, Friedmann PD, O’Toole TP (2011) Colocated general medical care and preventable hospital admissions for veterans with serious mental illness. Psychiatr Serv 62(5):554–557CrossRefPubMed
32.
Rumball-Smith J, Wodchis WP, Kone A, Kenealy T, Barnsley J, Ashton T (2014) Under the same roof: co-location of practitioners within primary care is associated with specialized chronic care management. BMC Fam Pract 15:149CrossRefPubMedPubMedCentral
33.
Chandhoke G, Wei X, Nanji S, Biagi J, Peng Y, Krzyzanowska M et al (2016) Patterns of referral for adjuvant chemotherapy for stage II and III colon cancer: a population-based study. Ann Surg Oncol 23(8):2529–2538CrossRefPubMed
34.
Poylin V, Curran T, Lee E, Nagle D (2014) Laparoscopic colectomy decreases the time to administration of chemotherapy compared with open colectomy. Ann Surg Oncol 21(11):3587–3591CrossRefPubMed
35.
Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A et al (2012) Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 23(5):1190–1197CrossRefPubMed
36.
Morris M, Platell C, Fritschi L, Iacopetta B (2007) Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer 96(5):701–707CrossRefPubMedPubMedCentral
37.
Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W (2006) Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 98(9):610–619CrossRefPubMed
38.
Ahmed S, Ahmad I, Zhu T, Arnold FP, Faiz Anan G, Sami A et al (2010) Early discontinuation but not the timing of adjuvant therapy affects survival of patients with high-risk colorectal cancer: a population-based study. Dis Colon Rectum 53(10):1432–1438CrossRefPubMed
Metadata
Title
Delivery of adjuvant chemotherapy among stage III colon cancer patients at a public versus private hospital in New York City
Authors
Daniel Lin
Judith D. Goldberg
Tsivia Hochman
Benjamin A. Levinson
Maria Khan
Elliot Newman
Lawrence P. Leichman
Heather T. Gold
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 2/2018
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0996-6

Other articles of this Issue 2/2018

Cancer Causes & Control 2/2018 Go to the issue

Original paper

Melanoma risk assessment based on relatives’ age at diagnosis

Original paper

Modifiable and non-modifiable risk factors for preterm delivery among adolescent and young adult cancer survivors

Original paper

Association between average daily television viewing time and the incidence of ovarian cancer: findings from the Japan Collaborative Cohort Study

Original paper

Rural–urban differences in surgical treatment, regional lymph node examination, and survival in endometrial cancer patients

Original paper

Current smoking is associated with a larger waist circumference and a more androgenic profile in young healthy women from high-risk breast cancer families

Original paper

Trends in prostate cancer incidence between 1996 and 2013 in two Swiss regions by age, grade, and T-stage
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits